

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	William A. Palmisano et al.	Examiner:	Alana Harris
Serial No.:	10/815,198	Group Art Unit:	1643
Filed:	March 25, 2004	Docket:	41543 US 0103
Title:	Cancer Monitoring by Aberrant Promotor Methylation of the Transcription Factor Genes PAX5 Alpha PAX5 Beta, Novel Loop Helix Loop Protein, Novel Gene 2, and Beta 3 Genes		

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the referenced materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(c)(1) and 37 C.F.R. §1.97(e)(1), Applicants state that each item of information contained in the Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Supplemental Information Disclosure Statement.

It is believed that no fee or statement is required with the Supplemental Information Disclosure Statement.

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Pursuant to 37 C.F.R. 1.98(a)(2), Applicant believes that copies of cited U.S. Patents and Published Applications are no longer required to be provided to the Office. Notification of this change was provided in the United States Patent and Trademark Office OG Notices dated October 12, 2004. Thus, Applicant has not included copies of any US Patents or Published

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Serial No :10/815,198

Page 2
Dkt: 41543 US 0103

Filing Date: March 25, 2004

Title: Cancer Monitoring by Aberrant Promotor Methylation of the Transcription Factor Genes PAX5 Alpha PAX5 Beta, Novel Loop Helix Loop Protein, Novel Gene 2, and Beta 3 Genes

Applications cited with this submission. Should the Office require copies to be provided, Applicant respectfully requests that notice of such requirement be directed to Applicant's below-signed representative. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).

Respectfully submitted,

WILLIAM A. PALMISANO ET AL.

By their Representatives,

PEACOCK MYERS, P.C.

P.O. Box 26927

Albuquerque, New Mexico 87125-6927

Telephone 505-998-6134

Date September 10, 2008

By



Janeen Vilven

Reg. No. 47,156

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 10th day of September, 2008.

Diane S. Nelson, Paralegal
Name


Signature